Elite in Hemolytic Transfusion Reaction

Pablo Bartolucci

Université Paris Est, 
Creteil, FR 
Elite in Hemolytic Transfusion Reaction
Université Paris Est, 
Creteil, FR 
OverviewLocationsClinical Research

Overview

Pablo Bartolucci practices in Creteil, France. Mr. Bartolucci is rated as an Elite expert by MediFind in the treatment of Hemolytic Transfusion Reaction. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hepato-Pancreato-Biliary Surgery, and Kidney Transplant.

His clinical research consists of co-authoring 158 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles in the study of Hemolytic Transfusion Reaction.

Gender
Male

Locations

Université Paris Est, Creteil, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Multicentre Randomized Double-blind Placebo-controlled Study to Evaluate the Effect on Albuminuria of 6 Months Treatment With Hydroxycarbamide (Siklos®) or a Placebo in Adults With Sickle Cell Disease:
Multicentre Randomized Double-blind Placebo-controlled Study to Evaluate the Effect on Albuminuria of 6 Months Treatment With Hydroxycarbamide (Siklos®) or a Placebo in Adults With Sickle Cell Disease:
Enrollment Status: Completed
Publish Date: May 14, 2025
Intervention Type: Drug
Study Drug: Hydroxycarbamide
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Multicenter Randomized Trial to Evaluate the Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients (CAMOVID)
A Multicenter Randomized Trial to Evaluate the Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients (CAMOVID)
Enrollment Status: Terminated
Publish Date: February 10, 2022
Intervention Type: Drug
Study Drug: Camostat
Study Phase: Phase 3
ESCORT-HU : European Sickle Cell Disease Cohort - Hydroxyurea
ESCORT-HU : European Sickle Cell Disease Cohort - Hydroxyurea
Enrollment Status: Completed
Publish Date: March 19, 2020
Intervention Type: Drug
View 3 Less Clinical Trials

158 Total Publications

High flow oxygen for vaso-occlusive crisis: a multicentre, prospective, randomised, multi-arm, multi-stage clinical trial (OSONE).
High flow oxygen for vaso-occlusive crisis: a multicentre, prospective, randomised, multi-arm, multi-stage clinical trial (OSONE).
Journal: BMJ open
Published: September 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bartolucci's expertise for a condition
ConditionClose
View All 7 Elite Conditions
    View All 29 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile